Erasca shares cut in half after patient death in clinical trial

Investing.com -- Erasca Inc. shares fell as much as 55% on Tuesday after the cancer-drug developer disclosed that a patient died following severe side effects from its experimental treatment.

The San Diego-based company said a 66-year-old man went to the emergency room with severe lung inflammation about a month after beginning the therapy. The patient withdrew from the clinical trial and later died after stopping the treatment.

Erasca released the information alongside data from an early-stage trial of its experimental therapy for pancreatic and lung cancer. The company said the treatment was generally well-tolerated with mostly low-grade side events.

You May Also Be Interested In

• Alphabet Sees FY26 Capex $195B To $205B, Saw $180B To $190B
• NB Bancorp, Inc. (NBBK) Tops Q2 EPS by 14c
• Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Insulet Corporation (NASDAQ: PODD); Photronics, Inc. (NASDAQ: PLAB); and Via Transportation, Inc. (NYSE: VIA): Grabar Law Office is Inv